Last reviewed · How we verify
TCA treatment
TCA treatment refers to tricyclic antidepressant therapy, which blocks the reuptake of norepinephrine and serotonin at neuronal synapses to increase their availability in the central nervous system.
TCA treatment refers to tricyclic antidepressant therapy, which blocks the reuptake of norepinephrine and serotonin at neuronal synapses to increase their availability in the central nervous system. Used for Major depressive disorder, Chronic pain conditions, Neuropathic pain.
At a glance
| Generic name | TCA treatment |
|---|---|
| Sponsor | Radboud University Medical Center |
| Drug class | Tricyclic antidepressant |
| Target | Norepinephrine transporter (NET), Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Tricyclic antidepressants (TCAs) inhibit the reuptake transporters for norepinephrine and serotonin, prolonging the presence of these neurotransmitters in the synaptic cleft. This increased neurotransmitter availability enhances monoaminergic signaling in the brain. TCAs also have anticholinergic and antihistamine properties that contribute to their therapeutic and adverse effects.
Approved indications
- Major depressive disorder
- Chronic pain conditions
- Neuropathic pain
- Migraine prophylaxis
- Anxiety disorders
Common side effects
- Dry mouth
- Constipation
- Sedation
- Orthostatic hypotension
- Cardiac arrhythmias
- Weight gain
- Blurred vision
Key clinical trials
- Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments (PHASE2)
- Study of the Effectiveness of a Systematic Minimal Early Intervention on Care Engagement in Adults With Eating Disorders Requesting Specialized Treatment. (NA)
- Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer (NA)
- MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC (PHASE2)
- Could Intralesional Steroid be the Novel Treatment for Granulomatous Mastitis? (NA)
- Molecule Removal and Ease of Use: A Comparison of Two Different Dialyzers (NA)
- Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes (PHASE4)
- Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TCA treatment CI brief — competitive landscape report
- TCA treatment updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI